Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone for Pathological Gambling
NCT01057862Phase 2Completed
- Sponsor
- Yale University
- Start
- Feb 2009
- Primary completion
- Feb 2016
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of naltrexone in gambling disorder (GD), sponsored by Yale University. Primary endpoint: Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling. Started Feb 2009; status: completed.
02
Drugs
naltrexone
03
Conditions
gambling disorder (GD)
Beyond the preview
Go deeper on NCT01057862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01057862.